BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Artemis II astronauts channel Apollo 8 with a striking Earthset photo- Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- Track down Your Optimal Conservative Vehicle: Famous Brands to Consider
- Vote in favor of the pasta that makes good dieting pleasant!
- Change Your Physical make-up: Compelling Activities for Muscle Building
- Iran war upends aviation strategies
- Defence chiefs of Thailand and Cambodia to discuss ceasefire
- German economic institutes cut forecast in half over Iran war
- Unsold Rams May Be Less expensive Than You Suspect
